SCHEMBL2197666

SCHEMBL2197666

COc1ccc(Cn2ccn(C)c2=[Pt])cc1.Cc1ccc(CN(I)I)cc1C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.40
LMNA P02545 4/20 0.39
TP53 P04637 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
NPBWR1 P48145 1/20 0.38
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
LPO P22079 2/20 0.36
POLB P06746 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
DCTPP1 Q9H773 1/20 0.36
ALDH1A1 P00352 2/20 0.35
KDM4E B2RXH2 1/20 0.35
ALOX15 P16050 1/20 0.35
KCNA5 P22460 2/20 0.33
MAPK1 P28482 1/20 0.33
SIRT5 Q9NXA8 1/20 0.33
CMA1 P23946 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2198406 0.89 LPO (0.51) MAPTLMNATP53MEN1KMT2A
SCHEMBL2194320 0.87 MAPT (0.42) MAPTLMNATP53MEN1KMT2A
SCHEMBL2195518 0.87 DBH (0.38) MAPTLMNAMEN1KMT2APOLB
SCHEMBL2198394 0.85 MAPT (0.42) MAPTLMNATP53NPBWR1LPO
SCHEMBL2194976 0.85 SIGMAR1 (0.44) MAPTLMNATP53L3MBTL1MEN1
SCHEMBL2195985 0.84 MAPT (0.38) MAPTLMNATP53L3MBTL1MEN1
SCHEMBL2193843 0.84 MET (0.43) MAPTLMNATP53MEN1KMT2A
SCHEMBL2195721 0.83 MAPT (0.36) MAPTLMNASMN1; SMN2ALDH1A1KDM4E
SCHEMBL2196877 0.82 LMNA (0.32) LMNA
SCHEMBL2197079 0.82 S1PR1 (0.35) LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8980875-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2015-03-17 US claimed
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-12-19 US claimed
US-8481522-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-07-09 US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 MAPT 4712/4885LMNA 2301/4885TP53 1327/4885
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 MAPT 4712/4885LMNA 2301/4885TP53 1327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.